[1]
A. H. Kumar, “Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy”, BEMS Reports, vol. 7, no. 2, pp. 21–24, Oct. 2021.